Should I buy or sell Avenue Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avenue Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATXI shares. View ATXI analyst ratings or view top-rated stocks .

How have ATXI shares performed in 2024?

Avenue Therapeutics' stock was trading at $0.1610 on January 1st, 2024. Since then, ATXI stock has decreased by 16.4% and is now trading at $0.1346. View the best growth stocks for 2024 here .

Are investors shorting Avenue Therapeutics?

Avenue Therapeutics saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 283,100 shares, a decline of 9.7% from the March 15th total of 313,400 shares. Based on an average daily volume of 2,290,000 shares, the days-to-cover ratio is presently 0.1 days. View Avenue Therapeutics' Short Interest .

When is Avenue Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our ATXI earnings forecast .

How were Avenue Therapeutics' earnings last quarter?

Avenue Therapeutics, Inc. (NASDAQ:ATXI) issued its quarterly earnings results on Monday, March, 18th. The company reported $0.56 earnings per share (EPS) for the quarter.

When did Avenue Therapeutics' stock split?

Avenue Therapeutics's stock reverse split on the morning of Friday, September 23rd 2022. The 1-15 reverse split was announced on Friday, September 23rd 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Avenue Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avenue Therapeutics investors own include Gilead Sciences (GILD) , AbbVie (ABBV) , Fulcrum Therapeutics (FULC) , SCYNEXIS (SCYX) , Sorrento Therapeutics (SRNE) , Allena Pharmaceuticals (ALNA) , Actinium Pharmaceuticals (ATNM) , CymaBay Therapeutics (CBAY) , CytomX Therapeutics (CTMX) and Spero Therapeutics (SPRO) .

When did Avenue Therapeutics IPO?

Avenue Therapeutics (ATXI) raised $30 million in an initial public offering on Tuesday, June 27th 2017. The company issued 5,000,000 shares at a price of $5.00-$7.00 per share. Oppenheimer acted as the underwriter for the IPO and National Securities Corp. was co-manager.

How do I buy shares of Avenue Therapeutics?

Shares of ATXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ATXI

Avenue Therapeutics (ATXI) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free ATXI Stock Alerts

$0.13

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.13
▼
$0.14
50-Day Range: $0.13
▼
$0.19
52-Week Range: $0.11
▼
$1.25

Volume: 290,143 shs
Average Volume: 872,280 shs
Market Capitalization: $5.96 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Avenue Therapeutics alerts:

Ad Altimetry

I’m officially sounding the alarm.

AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.

Just click here to watch my full uncensored interview.

About Avenue Therapeutics Stock (NASDAQ:ATXI)

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.

ATXI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ATXI Stock News Headlines

April 17, 2024 | americanbankingnews.com

Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Down 9.7% in March

April 5, 2024 | msn.com

Saks Fifth Avenue set to close at Fashion Mall at Keystone

April 19, 2024 | Altimetry (Ad)

I’m officially sounding the alarm.

April 5, 2024 | msn.com

2 suspects identified in connection with Euclid Avenue shooting: Mobile Police

April 5, 2024 | msn.com

New updates on revitalizations of Nashville’s 2nd Avenue years after Christmas Day bombing

April 5, 2024 | msn.com

Burbank Man Found Deceased In Bus Shelter On Harlem Avenue

April 5, 2024 | msn.com

Downtown Minneapolis' First Avenue N. corridor to get $30 million facelift, first big upgrade in decades

April 5, 2024 | yahoo.com

Fatal crash shuts down I-43 southbound at Hampton Avenue for hours

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 4, 2024 | msn.com

Tasing reported on Washington Avenue in North Avondale

April 4, 2024 | msn.com

House containing adults and child damaged by gunfire on Lyell Avenue

April 4, 2024 | msn.com

Police investigating school bus crash on Colerain Avenue in Mount Airy

April 3, 2024 | msn.com

Roc Paint Division brings Boston artist for 'caring' mural at Avenue D R-Center

April 3, 2024 | msn.com

Shooting reported on Glenwood Avenue in Avondale

April 3, 2024 | msn.com

Wires reported down on Pennsylvania Avenue in York City

April 3, 2024 | msn.com

Recycling truck dumps smoldering load on Summit Avenue. A lithium battery was likely to blame.

April 3, 2024 | yahoo.com

Man connected to two Worth Avenue jewelry store smash and grabs is charged in a third

April 3, 2024 | msn.com

Vehicle crash reported on Tokay Avenue in Modesto

April 3, 2024 | msn.com

Jerome Avenue Bridge to temporarily close for reconstruction project

April 3, 2024 | bizjournals.com

Longtime Dallas bar Stoneleigh P preps for move to Lemmon Avenue from Uptown

April 2, 2024 | yahoo.com

Neighbors concerned by growing encampment near 8th Avenue and Navajo Street

April 2, 2024 | msn.com

Lowry Avenue reconstruction project in northeast Minneapolis set to begin in mid-April

April 2, 2024 | msn.com

Fire causes heavy damage to Rockford home on Oakwood Avenue

April 2, 2024 | bizjournals.com

Proposed rezone on Watt Avenue in North Highlands would allow housing, retail on four different parcels

April 2, 2024 | msn.com

Pete Buttigieg coming to Birmingham on Wednesday to celebrate $14.5 million grant for 4th Avenue

April 2, 2024 | msn.com

Bristol’s Randall Avenue Bridge Set for $2 Million Makeover

April 2, 2024 | msn.com

CLSA raises target price for Avenue Supermarts to Rs 5,514, second upgrade in a week

See More Headlines

Receive ATXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/18/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ATXI
CUSIP: N/A
CIK: 1644963
Web: www.avenuetx.com
Phone: (781) 652-4500
Fax: N/A
Employees: 3
Year Founded: 2015

Profitability

EPS (Most Recent Fiscal Year): ($1.27)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,380,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -335.11%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.55
Quick Ratio: 1.55

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.03 per share
Price / Book: 4.49

Miscellaneous

Outstanding Shares: 44,260,000
Free Float: 43,464,000
Market Cap: $5.96 million
Optionable: Not Optionable
Beta: -0.24

Social Links

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. Alexandra MacLean M.D. (Age 56)
CEO & Director
Comp: $413.2k
Mr. David Jin (Age 33)
Interim CFO, COO & Corporate Secretary
Dr. Lindsay Allan Rosenwald (Age 69)
Executive Director
Dr. Xiaoqin Lu M.D. (Age 49)
Consultant
Comp: $1.05M
Dr. Scott A. Reines M.D. (Age 77)
Ph.D., Interim Chief Medical Officer
Comp: $69.12k
Mr. Srinivas Subramanian (Age 53)
Executive Vice President

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

ATXI Stock Analysis - Frequently Asked Questions

Should I buy or sell Avenue Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avenue Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATXI shares.
View ATXI analyst ratings or view top-rated stocks.
How have ATXI shares performed in 2024?: Avenue Therapeutics' stock was trading at $0.1610 on January 1st, 2024. Since then, ATXI stock has decreased by 16.4% and is now trading at $0.1346.
View the best growth stocks for 2024 here.
Are investors shorting Avenue Therapeutics?: Avenue Therapeutics saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 283,100 shares, a decline of 9.7% from the March 15th total of 313,400 shares. Based on an average daily volume of 2,290,000 shares, the days-to-cover ratio is presently 0.1 days.
View Avenue Therapeutics' Short Interest.
When is Avenue Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our ATXI earnings forecast.
How were Avenue Therapeutics' earnings last quarter?: Avenue Therapeutics, Inc. (NASDAQ:ATXI) issued its quarterly earnings results on Monday, March, 18th. The company reported $0.56 earnings per share (EPS) for the quarter.

When did Avenue Therapeutics' stock split?: Avenue Therapeutics's stock reverse split on the morning of Friday, September 23rd 2022. The 1-15 reverse split was announced on Friday, September 23rd 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What other stocks do shareholders of Avenue Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Avenue Therapeutics investors own include Gilead Sciences (GILD), AbbVie (ABBV), Fulcrum Therapeutics (FULC), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Actinium Pharmaceuticals (ATNM), CymaBay Therapeutics (CBAY), CytomX Therapeutics (CTMX) and Spero Therapeutics (SPRO).
When did Avenue Therapeutics IPO?: Avenue Therapeutics (ATXI) raised $30 million in an initial public offering on Tuesday, June 27th 2017. The company issued 5,000,000 shares at a price of $5.00-$7.00 per share. Oppenheimer acted as the underwriter for the IPO and National Securities Corp. was co-manager.
How do I buy shares of Avenue Therapeutics?: Shares of ATXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ATXI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Avenue Therapeutics (ATXI) Stock Price, News & Analysis

About Avenue Therapeutics Stock (NASDAQ:ATXI)

ATXI Stock Price History

ATXI Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders

ATXI Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info